Article
Profiling of defense responses in Escherichia coli treated with fosmidomycin.
Biochimie - 1 Apr 2014
Hemmerlin Andréa, Tritsch Denis, Hammann Philippe, Rohmer Michel, Bach Thomas J
Abstract excerpt
The mevalonate-independent isoprenoid biosynthesis pathway has been recognized as a promising target for designing new antibiotics. But pathogens treated with compounds such as fosmidomycin, a slow binding inhibitor of 1-deoxy-D-xylulose 5-phosphate reducto-isomerase, the second enzyme in this pathway, develop rapid drug resistance. In Escherichia coli, acquired resistance results mostly from inactivating the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
